Relationship between HLA-DRB1*0101, DRB1*0301 alleles and interleukin-12 in haemophilic patients and hepatitis C virus positive hepatocellular carcinoma patients.
The immune system can effectively eliminate hepatitis C virus (HCV) in 15 % of acute hepatitis cases. It is assumed that certain HLA-DR alleles present HCV epitopes more effectively to CD4 helper T cells than do others resulting in vigorous proliferative response to these epitopes and probably HCV recovery. So, we aimed at investigating the frequency of HLA-DRB1*0101 and DRB1*0301 alleles in child and adult haemophilics and in HCV positive hepatocellular carcinoma (HCC) patients in a trial to predict patients who require early therapeutic intervention. We also evaluated interleukin (IL)-12 levels in these patients since IL-12 induces interferon (IFN)-gamma production. This study was conducted on 50 antiHIV negative male patients subdivided into: 25 HCV negative haemophilics (group I), 10 HCV positive haemophilics (group II) and 15 HCV positive HCC (group III). Fifteen healthy persons of matched age and free of HCV and HIV infections were chosen as controls (group IV). All patients and controls were subjected to thorough history taking and clinical examination, routine and diagnostic investigations, viral markers, DRB1*0101 and DRB1*0301 amplification by polymerase chain reaction and plasma IL-12 quantitation by enzyme linked immunosorbent assay (ELISA). The frequencies of DRB1*0101 and DRB1*0301 were 20% and 30% respectively in HCV positive haemophilics and 13.3% and 40%, respectively in HCC. IL-12 levels were significantly lower in HCC cases than in HCV positive haemophilics. Among the haemophilics, IL-12 levels were non-significantly higher in children than in adults and were associated with the given number of blood product bags. DRB1*0101 and DRB1*0301 may have a role in HCV clearance and persistence in Egyptian patients with haemophilia and HCC. Low IL-12 levels encountered in HCV positive haemophilics suggest its relation to immunopathogenesis and outcome of HCV infection.
Hamed
Nahla A M
NA
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Hano
Abdel Fatah
AF
Raouf
Hala Abdel
HA
Gamal
Mona
M
Eissa
Maged
M
D000293:Adolescent; D000328:Adult; D000483:Alleles; D001483:Base Sequence; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000235:genetics* / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D004247:DNA / Q000235:genetics; D004534:Egypt; D015234:HLA-A Antigens / Q000235:genetics*; D006684:HLA-DR Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006467:Hemophilia A / Q000235:genetics* / Q000276:immunology*; D002836:Hemophilia B / Q000235:genetics* / Q000276:immunology*; D006526:Hepatitis C / Q000150:complications / Q000235:genetics* / Q000276:immunology* / Q000821:virology; D006801:Humans; D018664:Interleukin-12 / Q000097:blood*; D008113:Liver Neoplasms / Q000150:complications / Q000235:genetics* / Q000276:immunology*; D008297:Male
D015234:HLA-A Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C487961:HLA-DRB1*01:01 antigen; C553502:HLA-DRB1*03:01 antigen; D018664:Interleukin-12; D004247:DNA